We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

Fund managers haven’t disclosed any holdings of OTLK yet.

OTLK Hedge Fund Activity: Q1 2026 in Review

54 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2026, worth a combined $2.21M — down 80% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new OTLK positions and 14 closed out — a net gain of 2 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.8M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $3.86M sold.

  • 54 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2026, up from 53 in Q4 2025.
  • Funds reported $2.21M of Outlook Therapeutics stock for Q1 2026, down 80% quarter-over-quarter.
  • 16 funds opened new Outlook Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
  • The largest Outlook Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $1.8M added.
  • The largest Outlook Therapeutics seller in Q1 2026 was Schonfeld Strategic Advisors, an estimated $3.86M sold.

Based on aggregated 13F filings for Q1 2026.